DK1924574T3 - Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin - Google Patents
Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenaminInfo
- Publication number
- DK1924574T3 DK1924574T3 DK06772448.4T DK06772448T DK1924574T3 DK 1924574 T3 DK1924574 T3 DK 1924574T3 DK 06772448 T DK06772448 T DK 06772448T DK 1924574 T3 DK1924574 T3 DK 1924574T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzenamine
- imidazol
- trifluoromethyl
- synthesis
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68897705P | 2005-06-09 | 2005-06-09 | |
| US70559005P | 2005-08-04 | 2005-08-04 | |
| PCT/US2006/022155 WO2006135641A2 (en) | 2005-06-09 | 2006-06-07 | PROCESS FOR THE SYNTHESIS OF 5- (METHYL-lH-IMIDAZOL-l-YL) -3- (TRI FLUOROME TH YL) -BENZENEAMINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1924574T3 true DK1924574T3 (da) | 2011-02-14 |
Family
ID=37091153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06772448.4T DK1924574T3 (da) | 2005-06-09 | 2006-06-07 | Fremgangsmåde til syntese af 5-(methyl-1H-imidazol-1-yl)-3-(trifluormethyl)-benzenamin |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8124763B2 (enExample) |
| EP (1) | EP1924574B1 (enExample) |
| JP (1) | JP5118024B2 (enExample) |
| KR (3) | KR20120066067A (enExample) |
| AR (1) | AR053890A1 (enExample) |
| AT (1) | ATE487709T1 (enExample) |
| AU (1) | AU2006258051B2 (enExample) |
| BR (1) | BRPI0611663A2 (enExample) |
| CA (1) | CA2610105C (enExample) |
| CY (1) | CY1111428T1 (enExample) |
| DE (1) | DE602006018156D1 (enExample) |
| DK (1) | DK1924574T3 (enExample) |
| EC (1) | ECSP077982A (enExample) |
| EG (1) | EG25039A (enExample) |
| GT (1) | GT200600217A (enExample) |
| IL (1) | IL187421A (enExample) |
| JO (1) | JO2636B1 (enExample) |
| MA (1) | MA29599B1 (enExample) |
| MX (1) | MX2007015423A (enExample) |
| MY (1) | MY147436A (enExample) |
| NO (1) | NO340743B1 (enExample) |
| NZ (1) | NZ563740A (enExample) |
| PE (1) | PE20070015A1 (enExample) |
| PL (1) | PL1924574T3 (enExample) |
| PT (1) | PT1924574E (enExample) |
| RU (1) | RU2444520C2 (enExample) |
| SA (1) | SA06270147B1 (enExample) |
| SI (1) | SI1924574T1 (enExample) |
| TN (1) | TNSN07463A1 (enExample) |
| TW (1) | TWI430999B (enExample) |
| WO (1) | WO2006135641A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| EP2305667A3 (en) | 2008-07-17 | 2011-05-11 | Teva Pharmaceutical Industries Ltd. | Nilotinib intermediates and preparation thereof |
| HRP20120793T1 (hr) | 2008-11-05 | 2012-12-31 | Teva Pharmaceutical Industries Ltd. | Kristalni oblici nilotinib hci |
| WO2010060074A1 (en) * | 2008-11-24 | 2010-05-27 | Teva Pharmaceutical Industries Ltd. | Preparation of nilotinib and intermediates thereof |
| US20110053968A1 (en) | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| JO3634B1 (ar) | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
| JP5841234B2 (ja) | 2011-03-31 | 2016-01-13 | ザ プロクター アンド ギャンブルカンパニー | フケ／脂漏性皮膚炎の治療に有効な皮膚活性剤を特定及び評価するためのシステム、モデル、及び方法 |
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| GB2514285B (en) | 2012-02-13 | 2018-07-18 | Grindeks Jsc | Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors |
| MX2014014898A (es) | 2012-06-06 | 2015-03-04 | Procter & Gamble | Sistemas y metodos de identificacion de agentes cosmeticos para composiciones para el cuidado del cabello/cuero cabelludo. |
| WO2015092624A1 (en) | 2013-12-16 | 2015-06-25 | Ranbaxy Laboratories Limited | Nilotinib mono-oxalate and its crystalline form |
| CN103694176B (zh) | 2014-01-07 | 2015-02-18 | 苏州立新制药有限公司 | 尼洛替尼中间体的制备方法 |
| EP3095782A1 (en) | 2015-05-18 | 2016-11-23 | Esteve Química, S.A. | New method for preparing 3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)benzenamine |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
| TWI787523B (zh) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
| JP2020007240A (ja) * | 2018-07-04 | 2020-01-16 | 住友化学株式会社 | ベンズアミド化合物の製造方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5136082A (en) * | 1990-08-03 | 1992-08-04 | Himont Incorporated | Process for preparing organic esters and amides and catalyst system therefor |
| AU5539294A (en) | 1992-12-24 | 1994-07-19 | Hemagen/Pfc | Fluorocarbon emulsions |
| TW406020B (en) | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5597829A (en) | 1994-05-09 | 1997-01-28 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of camptothecin and methods for uses thereof |
| US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
| US6323366B1 (en) | 1997-07-29 | 2001-11-27 | Massachusetts Institute Of Technology | Arylamine synthesis |
| AR013261A1 (es) | 1997-08-01 | 2000-12-13 | Smithkline Beecham Corp | Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina |
| US20030059465A1 (en) | 1998-05-11 | 2003-03-27 | Unger Evan C. | Stabilized nanoparticle formulations of camptotheca derivatives |
| US6395916B1 (en) | 1998-07-10 | 2002-05-28 | Massachusetts Institute Of Technology | Ligands for metals and improved metal-catalyzed processes based thereon |
| DK1044977T3 (da) | 1999-03-09 | 2002-07-08 | Sigma Tau Ind Farmaceuti | Camptothecinderivater med antitumoraktivitet |
| IT1306129B1 (it) | 1999-04-13 | 2001-05-30 | Sigma Tau Ind Farmaceuti | Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti |
| DE19926056B4 (de) | 1999-06-08 | 2004-03-25 | Gkss-Forschungszentrum Geesthacht Gmbh | Einrichtung zur Analyse atomarer und/oder molekularer Elemente mittels wellenlängendispersiver, röntgenspektrometrischer Einrichtungen |
| GB9918885D0 (en) | 1999-08-10 | 1999-10-13 | Pharmacia & Upjohn Spa | Pharmaceutical formulations in hydroxypropymethycellulose capsules |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| US20040009229A1 (en) | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
| US20020150615A1 (en) | 2001-02-12 | 2002-10-17 | Howard Sands | Injectable pharmaceutical composition comprising microdroplets of a camptothecin |
| US6629598B2 (en) | 2001-08-10 | 2003-10-07 | Vinod K. Narula | Flexible ribbed splint system |
| US6653319B1 (en) | 2001-08-10 | 2003-11-25 | University Of Kentucky Research Foundation | Pharmaceutical formulation for poorly water soluble camptothecin analogues |
| WO2003032906A2 (en) | 2001-10-15 | 2003-04-24 | Crititech, Inc. | Delivery of poorly soluble drugs |
| US20060078618A1 (en) | 2001-12-11 | 2006-04-13 | Constantinides Panayiotis P | Lipid particles and suspensions and uses thereof |
| JP2003267891A (ja) | 2002-03-13 | 2003-09-25 | Mitsubishi-Kagaku Foods Corp | Ｗ／ｏ／ｗ型エマルション製剤 |
| US7202367B2 (en) | 2002-05-31 | 2007-04-10 | Rhodia Chimie | Process for arylating or vinylating or alkynating a nucleophilic compound |
| CZ294371B6 (cs) | 2002-06-10 | 2004-12-15 | Pliva - Lachema, A. S. | Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy |
| EP1393719A1 (en) | 2002-08-23 | 2004-03-03 | Munich Biotech AG | Camptothecin-carboxylate formulations |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| JP4426749B2 (ja) | 2002-07-11 | 2010-03-03 | 株式会社産学連携機構九州 | Ｏ／ｗ型エマルション製剤 |
| US20040171560A1 (en) | 2002-12-23 | 2004-09-02 | Dabur Research Foundation | Stabilized pharmaceutical composition |
| JP2006199590A (ja) | 2003-09-04 | 2006-08-03 | Nano Career Kk | 水溶性の塩基性薬物内包ナノ粒子含有組成物 |
| CA2543722C (en) | 2003-10-29 | 2011-01-04 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
| DK1694242T3 (da) | 2003-12-17 | 2014-06-30 | Bionumerik Pharmaceuticals Inc | Fremgangsmåde til fremstilling af farmaceutiske 7-(2-trimethylsilylethyl)camptothecinpræparater |
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos |
-
2006
- 2006-05-23 SA SA06270147A patent/SA06270147B1/ar unknown
- 2006-05-24 GT GT200600217A patent/GT200600217A/es unknown
- 2006-05-31 MY MYPI20062507A patent/MY147436A/en unknown
- 2006-06-06 JO JO2006166A patent/JO2636B1/en active
- 2006-06-07 SI SI200630903T patent/SI1924574T1/sl unknown
- 2006-06-07 AT AT06772448T patent/ATE487709T1/de active
- 2006-06-07 KR KR1020127011980A patent/KR20120066067A/ko not_active Ceased
- 2006-06-07 PE PE2006000631A patent/PE20070015A1/es not_active Application Discontinuation
- 2006-06-07 CA CA2610105A patent/CA2610105C/en not_active Expired - Lifetime
- 2006-06-07 DK DK06772448.4T patent/DK1924574T3/da active
- 2006-06-07 KR KR1020077028638A patent/KR101216249B1/ko not_active Expired - Lifetime
- 2006-06-07 DE DE602006018156T patent/DE602006018156D1/de not_active Expired - Lifetime
- 2006-06-07 AR ARP060102369A patent/AR053890A1/es not_active Application Discontinuation
- 2006-06-07 EP EP06772448A patent/EP1924574B1/en not_active Expired - Lifetime
- 2006-06-07 US US11/915,671 patent/US8124763B2/en active Active
- 2006-06-07 PL PL06772448T patent/PL1924574T3/pl unknown
- 2006-06-07 BR BRPI0611663-9A patent/BRPI0611663A2/pt not_active Application Discontinuation
- 2006-06-07 PT PT06772448T patent/PT1924574E/pt unknown
- 2006-06-07 WO PCT/US2006/022155 patent/WO2006135641A2/en not_active Ceased
- 2006-06-07 RU RU2007148231/04A patent/RU2444520C2/ru active
- 2006-06-07 NZ NZ563740A patent/NZ563740A/en not_active IP Right Cessation
- 2006-06-07 MX MX2007015423A patent/MX2007015423A/es active IP Right Grant
- 2006-06-07 JP JP2008515881A patent/JP5118024B2/ja not_active Expired - Lifetime
- 2006-06-07 AU AU2006258051A patent/AU2006258051B2/en not_active Expired
- 2006-06-07 KR KR1020137025659A patent/KR101514593B1/ko not_active Expired - Lifetime
- 2006-06-08 TW TW095120302A patent/TWI430999B/zh not_active IP Right Cessation
-
2007
- 2007-11-15 IL IL187421A patent/IL187421A/en active IP Right Grant
- 2007-12-05 EC EC2007007982A patent/ECSP077982A/es unknown
- 2007-12-07 TN TNP2007000463A patent/TNSN07463A1/en unknown
- 2007-12-09 EG EGNA2007001382 patent/EG25039A/xx active
- 2007-12-26 MA MA30505A patent/MA29599B1/fr unknown
-
2008
- 2008-01-09 NO NO20080157A patent/NO340743B1/no unknown
-
2011
- 2011-02-04 CY CY20111100134T patent/CY1111428T1/el unknown
-
2012
- 2012-01-19 US US13/353,434 patent/US8946416B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284991A (en) | Antibodies against cd38 for treatment of multiple myeloma | |
| DK1795576T3 (da) | Fremgangsmåde til fremstilling af carbonhydrider | |
| DK2292607T3 (da) | Fremgangsmåde til syntese af organiske forbindelser | |
| DK1893586T3 (da) | Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler | |
| DK1877192T5 (da) | Fremgangsmåde til fremstilling af fibermateriale | |
| DK1973888T3 (da) | Isoxazoliner til bekæmpelse af hvirvelløse skadedyr | |
| DK1828164T3 (da) | Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider | |
| DK1778668T3 (da) | Fremgangsmåde til fremstilling af dihydropteridion | |
| DK2423325T3 (da) | Fremgangsmåde til fremstilling af biblioteker af template-polynukleotider | |
| DK2046767T3 (da) | Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser | |
| DK2781593T3 (da) | Fremgangsmåde til behandling af methanemissioner | |
| DK2207779T3 (da) | Fremgangsmåde til syntese af morpholinooligomerer | |
| DK2824183T3 (da) | Fremgangsmåde til fremstilling af bispecifikke antistoffer | |
| IL198186A (en) | Mphosph1 derived peptide vaccines | |
| DK2086944T3 (da) | Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater | |
| DK3336073T3 (da) | Fremgangsmåde til fremstilling af fluorerede organiske forbindelser | |
| IL187421A0 (en) | Process for the synthesis of 5-(methyl-1h-imidazol-1-yl)-3-(tri fluorome th yl)-benzeneamine | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DK1948176T3 (da) | Diarylurinstoffer til behandling af pulmonær hypertension | |
| DK1937650T3 (da) | Heterocykliske forbindelser | |
| DK1947933T4 (da) | System til styret udbringning af herbicider | |
| PL1896425T3 (pl) | Sposób wytwarzania 5-(metylo-1H-1-ilo)-3-trifluorometylo)-benzenoaminy | |
| DK4070800T3 (da) | Cladribinkur til behandling af multipel sklerose | |
| DK1881830T3 (da) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet | |
| DK1831223T3 (da) | Fremgangsmåde til fremstilling af L-biopterin |